UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

The lancet oncology, 2010, Vol.11 (1), p.21-28

2010

Volltextzugriff (PDF)

Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9394-9407

ROWINSKY, Eric K

2005

Volltextzugriff (PDF)

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Cell, 2018-02, Vol.172 (4), p.825-840.e18

2018

Volltextzugriff (PDF)

Raf: A Strategic Target for Therapeutic Development Against Cancer

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6771-6790

2005

Volltextzugriff (PDF)

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual review of medicine, 2004-01, Vol.55 (1), p.433-457

Rowinsky, Eric K

2004

Volltextzugriff (PDF)

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Journal of clinical oncology, 2010-02, Vol.28 (5), p.780-787

2010

Volltextzugriff (PDF)

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3238-3247

2004

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Volltextzugriff (PDF)

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4914-4921

2006

Volltextzugriff (PDF)

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Haematologica (Roma), 2015-02, Vol.100 (2), p.223-230

2015

Volltextzugriff (PDF)

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Volltextzugriff (PDF)

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Clinical cancer research, 2007-09, Vol.13 (18), p.5549s-5555s

2007

Volltextzugriff (PDF)

Targeting the molecular target of rapamycin (mTOR)

Current opinion in oncology, 2004-11, Vol.16 (6), p.564-575

Rowinsky, Eric K

2004

Volltextzugriff (PDF)

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Journal of clinical oncology, 2008-01, Vol.26 (3), p.361-367

2008

Volltextzugriff (PDF)

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

Journal of clinical oncology, 2003-02, Vol.21 (4), p.588-592

2003

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4707-4713

2007

Volltextzugriff (PDF)

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2240-2250

2002

Volltextzugriff (PDF)

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Volltextzugriff (PDF)

1 – 25 von 325

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library - AutoHoldings Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(305)
Mit Volltextzugriff
(312)

Publikationsform

Sprache

Englisch
(325)
Japanisch
(37)

Erscheinungsjahr

n.n

Thema

Humans
(227)
Life Sciences & Biomedicine
(195)
Science & Technology
(195)
Oncology
(194)
Biological And Medical Sciences
(170)
Medical Sciences
(170)
Pharmacology. Drug Treatments
(150)
Antineoplastic Agents
(149)
Female
(146)
Male
(136)
Middle Aged
(135)
Aged
(130)
Adult
(129)
Neoplasms - Drug Therapy
(108)
Chemotherapy
(97)
Dose-Response Relationship, Drug
(72)
Drug Administration Schedule
(58)
Tumors
(51)
Antineoplastic Agents - Therapeutic Use
(46)
Antineoplastic Agents - Adverse Effects
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Raf: A Strategic Target for Therapeutic Development Against Cancer

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Targeting the molecular target of rapamycin (mTOR)

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Aktive Filter

Suchergebnisse filtern